Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ELL
REST API REST API
Homo sapiens
ELL is differentially expressed in 198 experiments: 85 organism parts: testis, blood, ... (83 more);, 142 disease states: normal, acute myeloid leukemia, ... (140 more);, 61 cell types 148 cell lines 19 compound treatments and 60 other conditions.
Synonyms ELL1, Men, C19orf17
Orthologs Ell (Mus musculus)   Q5ZLS5_CHICK (Gallus gallus)   Ell (Rattus norvegicus)   ell (Danio rerio)   ELL (Bos taurus)   Su(Tpl) (Drosophila melanogaster)   ell (Xenopus laevis)   ENSXETG00000030690 (Xenopus laevis)   ELL (Canis familiaris)   (Compare orthologs)
Gene Ontology Term nuclear speck, regulation of transcription, DNA-dependent, Cajal body, transcription from RNA polymerase II promoter, nucleus, transcription elongation factor complex, nucleoplasm, viral reproduction, in utero embryonic development, gene expression, positive regulation of viral transcription, transcription elongation from RNA polymerase II promoter, positive regulation of transcription elongation, DNA-dependent
InterPro Term Occludin_RNApol2_elong_fac_ELL, RNA_pol_II_elong_fac_ELL
UniProt Accession P55199, Q75MS0
Search EB-eye ENSG00000105656
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (24 experiments)

Factor Value U/D Experiments
HL-60
1
E-GEOD-24147
NCIH2107
1
E-MTAB-37
LU139
1
E-MTAB-62
GDM1
1
E-MTAB-37
cal 27
1
E-MTAB-62
HDMYZ
1
E-MTAB-37
142 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-360, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (32 experiments)

Factor Value U/D Experiments
2
E-TABM-145, E-TABM-130
testis - germ cell
1
E-AFMX-5
BDCA3+ dendritic cell
1
1
E-TABM-34
PBMCs
1
E-GEOD-20677
not specified
1
E-GEOD-11755
dNK cell
1
E-GEOD-20499
55 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, ... (40 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
acute myelomonocytic leukemia
1
E-MTAB-62
Becker muscular dystrophy
1
E-GEOD-3307
endocarditis
1
E-MTAB-62
136 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5681, E-GEOD-5824, E-MEXP-1958, ... (14 experiments)

Factor Value U/D Experiments
none
1
5
E-MEXP-1958, E-GEOD-5681, E-GEOD-412, E-GEOD-5824, E-GEOD-7400, ... (6 experiments)
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
glutamine
1
E-MEXP-1335
estradiol
1
E-GEOD-20081
no estradiol
1
E-GEOD-20081
bacterial endotoxin
1
1
E-GEOD-3284
13 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-20499, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7578, E-MEXP-2340

Genotype
studied in E-TABM-763, E-GEOD-3494, E-MEXP-149, E-GEOD-2466, E-GEOD-17476, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-MEXP-1446, E-MEXP-2146 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-740, E-MEXP-1290, E-MEXP-2069, E-GEOD-1926, ... (22 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-2487, E-MEXP-1403

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-TABM-311, E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-22541, E-GEOD-4922

Processing time: 0.474 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM